Financing through stock acquisition rights with adjustment clauses for the exercise price
First written in FY2023-Q1. 13 of 15 entries say "Advanced", first in FY2023-Q2. Latest entry: 2026-08-14.
20 other companies' latest entry also says "Advanced".
- 2026-08-14AdvancedResults briefing materials
「2026年3月期に実施した新株予約権によるファイナンスの進捗状況につき、第14回は全株行使完了し、約41.8億円を資金調達。2026年2月・7月に使途変更を決定し、BTCの取得だけでなく、デジタルアセット全般の取得・AIDC開発・提携投資へ対象を拡大。」
第14回新株予約権の全株行使完了と調達額が示され、資金使途もBTC以外のデジタルアセット、AIDC開発、提携投資へ広がった。 - FY2026AdvancedAnnual report
「The company is acquiring and holding bitcoin using funds raised through MS warrants (stock acquisition rights with provisions for adjustment of the exercise price). As of the end of March 2026, it had raised approximately ¥2.491 billion and acquired 168.50 BTC.」
Funding through stock acquisition rights with provisions for adjustment of the exercise price progressed, with approximately ¥2.491 billion raised and 168.50 BTC acquired. - FY2026-H1AdvancedAnnual report
「14th series of share acquisition rights Common shares 1,000,000 The initial exercise price is ¥7,870. The exercise price of these share acquisition rights will be revised to an amount equivalent to 94% of the closing price.」
The 14th and 15th series of share acquisition rights were issued, with an exercise-price adjustment clause attached to the 14th series. Financing activities included ¥134.200 million in proceeds from the issuance of shares through the exercise of share acquisition rights. - FY2024AdvancedAnnual report
「Net cash provided by financing activities was ¥45.544 million, down 78.6% year on year. This was mainly due to proceeds of ¥45.672 million from the issuance of shares through the exercise of share acquisition rights.」
The company recorded proceeds of ¥45.672 million from the issuance of shares through the exercise of share acquisition rights, and financing and share issuance through share acquisition rights progressed during the fiscal year. - FY2024-Q2AdvancedAnnual report
「Net cash provided by financing activities was ¥45.544 million, up 544.5% year on year. This was mainly due to proceeds of ¥45.672 million from the issuance of shares through the exercise of share acquisition rights, among other factors.」
The company recorded proceeds of ¥45.672 million from the issuance of shares through the exercise of share acquisition rights, and financing and share issuance through share acquisition rights with an exercise-price adjustment clause progressed. - FY2024-Q1AdvancedAnnual report
「1 April 2023–30 June 2023 (Note) 1 40,800 2,632,859 22,431 899,734 22,431 841,361 (Note) 1. The increase resulted from the exercise of share acquisition rights.」
During the first quarter, 40,800 shares were issued through the exercise of share acquisition rights, increasing capital and capital surplus by ¥22.431 million each. Financing and share issuance through share acquisition rights progressed. - FY2023AdvancedAnnual report
「Net cash provided by financing activities was ¥213.295 million, up 405.3% year on year. This was due to proceeds of ¥208.305 million from the issuance of shares through the exercise of share acquisition rights.」
The company recorded proceeds of ¥208.305 million from the issuance of shares through the exercise of share acquisition rights, and issued an additional 192,300 shares during the fiscal year. - FY2023-Q3AdvancedAnnual report
「1 October 2022–31 December 2022 (Note) 114,200 2,517,059 62,787 836,067 62,787 777,694 (Note) Increase through the exercise of stock acquisition rights.」
During the third quarter accounting period, 114,200 shares were issued through the exercise of share acquisition rights, increasing capital and capital surplus by ¥62.787 million each. Financing and share issuance through share acquisition rights progressed. - FY2023-Q2AdvancedAnnual report
「Net cash provided by financing activities was ¥7.067 million, down 83.3% year on year. This was mainly due to proceeds of ¥4.990 million from the issuance of share acquisition rights, among other factors.」
The company recorded proceeds of ¥4.990 million from the issuance of share acquisition rights and proceeded with financing through share acquisition rights with an exercise-price adjustment clause. - FY2023-Q1First statedAnnual report
「The total number of shares underlying these share acquisition rights is fixed at 230,000 common shares of the company, and the number of shares allotted is fixed at 100. This number does not change even if the exercise price, as defined in Note 5 and hereinafter, is revised due to a rise or fall in the share price.」
The 10th series of share acquisition rights was issued for the period from 18 April 2022 to 17 April 2025, with 230,000 underlying shares, representing 9.6% of issued shares. The exercise price was subject to revision based on the share price, with a minimum exercise price of ¥496 and a minimum amount of funds raised of ¥116,288,000 if all rights were exercised.